GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oxford Cannabinoid Technologies Holdings PLC (FRA:0CB) » Definitions » Retained Earnings

Oxford Cannabinoid Technologies Holdings (FRA:0CB) Retained Earnings

: €-25.06 Mil (As of Oct. 2023)
View and export this data going back to 2021. Start your Free Trial

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Oxford Cannabinoid Technologies Holdings's retained earnings for the quarter that ended in Oct. 2023 was €-25.06 Mil.

Oxford Cannabinoid Technologies Holdings's quarterly retained earnings declined from Oct. 2022 (€-20.13 Mil) to Apr. 2023 (€-22.41 Mil) and declined from Apr. 2023 (€-22.41 Mil) to Oct. 2023 (€-25.06 Mil).

Oxford Cannabinoid Technologies Holdings's annual retained earnings declined from May. 2020 (€-6.59 Mil) to May. 2021 (€-10.51 Mil) and declined from May. 2021 (€-10.51 Mil) to Apr. 2023 (€-22.41 Mil).


Oxford Cannabinoid Technologies Holdings Retained Earnings Historical Data

The historical data trend for Oxford Cannabinoid Technologies Holdings's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oxford Cannabinoid Technologies Holdings Annual Data
Trend May18 May19 May20 May21 Apr23
Retained Earnings
-1.29 -4.31 -6.59 -10.51 -22.41

Oxford Cannabinoid Technologies Holdings Semi-Annual Data
May19 Nov19 May20 Nov20 May21 Nov21 Oct22 Apr23 Oct23
Retained Earnings Premium Member Only Premium Member Only Premium Member Only Premium Member Only -10.51 -13.09 -20.13 -22.41 -25.06

Oxford Cannabinoid Technologies Holdings Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.


Oxford Cannabinoid Technologies Holdings  (FRA:0CB) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.


Oxford Cannabinoid Technologies Holdings (FRA:0CB) Business Description

Traded in Other Exchanges
Address
267 Banbury Road, Prama House, Oxford, GBR, OX2 7HT
Oxford Cannabinoid Technologies Holdings PLC is a pharmaceutical company engaged in cannabinoid drug development. The company uses a drug development that includes proprietary cannabinoid derivatives, natural phytocannabinoids (pCBs), and in-licensed compounds. Its primary market focus is the pain market, and OCT initially aims to develop a portfolio of four drug candidates for approval as licensed pain medicines.

Oxford Cannabinoid Technologies Holdings (FRA:0CB) Headlines

No Headlines